Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data.
about
Comparison of Eylea® with Lucentis® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysisEffects of Aflibercept for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis of Observational Comparative Studies.Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland.Real world evidence of use of anti-VEGF therapy in Denmark.Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context.Omega-3 from Flaxseed Oil Protects Obese Mice Against Diabetic Retinopathy Through GPR120 Receptor
P2860
Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Anti-VEGF treatment patterns a ...... using real-world claims data.
@ast
Anti-VEGF treatment patterns a ...... using real-world claims data.
@en
type
label
Anti-VEGF treatment patterns a ...... using real-world claims data.
@ast
Anti-VEGF treatment patterns a ...... using real-world claims data.
@en
prefLabel
Anti-VEGF treatment patterns a ...... using real-world claims data.
@ast
Anti-VEGF treatment patterns a ...... using real-world claims data.
@en
P2093
P2860
P356
P1476
Anti-VEGF treatment patterns a ...... using real-world claims data.
@en
P2093
Jeremy P Howell
Livia Faes
Lucas M Bachmann
Mario Bittner
Martin K Schmid
Michael A Thiel
Oliver Reich
Sophie C Böhni
P2860
P356
10.2147/RMHP.S80536
P577
2015-04-21T00:00:00Z